A7655
阿替洛尔
≥98% (TLC), powder, β₁-adrenoceptor antagonist
别名:
(±)-4-[2-羟基-3-[（1-甲基乙基）氨基] 丙氧基] 苯乙酰胺, 4-[2′-羟基-3′-（异丙胺基）丙氧基] 苯乙酰胺
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C14H22N2O3
化学文摘社编号:
分子量:
266.34
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
249-451-7
MDL number:
产品名称
阿替洛尔, ≥98% (TLC), powder
InChI key
METKIMKYRPQLGS-UHFFFAOYSA-N
InChI
1S/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18)
SMILES string
CC(C)NCC(O)COc1ccc(CC(N)=O)cc1
assay
≥98% (TLC)
form
powder
color
white to off-white
solubility
H2O: 0.3 mg/mL
DMSO: 18 mg/mL
ethanol: 3.4 mg/mL
originator
AstraZeneca
Quality Level
Gene Information
human ... ADRB1(153)
rat ... Adrb1(24925)
正在寻找类似产品? 访问 产品对比指南
Application
阿替洛尔是一种 β 肾上腺素能受体阻断药，用于治疗高血压。阿替洛尔具有抗心绞痛和抗心律失常的作用。
Biochem/physiol Actions
选择性 β1 肾上腺素受体拮抗剂；抗高血压；抗心绞痛；抗心律失常。
Features and Benefits
该化合物由 AstraZeneca 公司开发。若要浏览其他制药公司研发的化合物和批准的药物/候选药物列表，请单击此处。
Other Notes
固体的有效期至少为 3 年。
存储类别
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
法规信息
监管及禁止进口产品
此项目有
Ganesha Rai et al.
Journal of medicinal chemistry, 52(20), 6474-6483 (2009-09-19)
Schistosomiasis is a chronic parasitic disease affecting hundreds of millions of individuals worldwide. Current treatment depends on a single agent, praziquantel, raising concerns of emergence of resistant parasites. Here, we continue our explorations of an oxadiazole-2-oxide class of compounds we
Hsin-Hui Chiu et al.
Mayo Clinic proceedings, 88(3), 271-276 (2013-01-17)
To assess the tolerability and efficacy of the investigational use of the angiotensin II receptor blocker losartan added to β-blockade (BB) to prevent progressive aortic root dilation in patients with Marfan syndrome (MFS). Between May 1, 2007, and September 31
Sripal Bangalore et al.
The American journal of medicine, 127(10), 939-953 (2014-06-15)
Debate exists about the efficacy of β-blockers in myocardial infarction and their required duration of usage in contemporary practice. We conducted a MEDLINE/EMBASE/CENTRAL search for randomized trials evaluating β-blockers in myocardial infarction enrolling at least 100 patients. The primary outcome
Ronald V Lacro et al.
American heart journal, 165(5), 828-835 (2013-04-30)
The Pediatric Heart Network designed a clinical trial to compare aortic root growth and other short-term cardiovascular outcomes in children and young adults with Marfan syndrome randomized to receive atenolol or losartan. We report here the characteristics of the screened
Ronald V Lacro et al.
The New England journal of medicine, 371(22), 2061-2071 (2014-11-19)
Aortic-root dissection is the leading cause of death in Marfan's syndrome. Studies suggest that with regard to slowing aortic-root enlargement, losartan may be more effective than beta-blockers, the current standard therapy in most centers. We conducted a randomized trial comparing
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持